QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors

Non-small Cell Lung Cancer Clinical Trial

Official title:

NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With Programmed Cell Death Protein 1 (PD-1)/Programmed Death-ligand 1 (PD-L1) Inhibitors

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03169738
• Other study ID #: QUILT-3.044
• Status: Withdrawn
• Phase: Phase 1/Phase 2
• Start date: February 2018
• Est. completion date: March 2019

Study information

• Verified date: October 2017
• Source: ImmunityBio, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with NSCLC who have progressed on or after treatment with PD-1/PD-L1 inhibitors.

Description:

Treatment will be administered in 2 phases, an induction and a maintenance phase, as described below. Subjects will continue induction treatment for up to 1 year. Treatment in the study will be discontinued if the subject experiences progressive disease (PD) or unacceptable toxicity (not correctable with dose reduction), withdraws consent, or if the Investigator feels it is no longer in the subject's best interest to continue treatment. Those who have a complete response (CR) in the induction phase will enter the maintenance phase of the study. Subjects may remain on the maintenance phase of the study for up to 1 year. Treatment will continue in the maintenance phase until the subject experiences PD or unacceptable toxicity (not correctable with dose reduction), withdraws consent, or if the Investigator feels it is no longer in the subject's best interest to continue treatment.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: March 2019
• Est. primary completion date: January 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age = 18 years.

2. Able to understand and provide a signed informed consent that fulfills the relevant Institutional Review Board (IRB) or Independent Ethics Committee (IEC) guidelines.

3. Histologically-confirmed NSCLC with progression on or after treatment with PD-1/PD-L1 inhibitors for their indicated usages.

4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

5. Have at least 1 measurable lesion of = 1.5 cm.

6. Must have a recent tumor biopsy specimen obtained following the conclusion of the most recent anti-cancer treatment. If an historic specimen is not available, the subject must be willing to undergo a biopsy during the screening period.

7. Must be willing to provide blood samples and, if considered safe by the Investigator, a tumor biopsy specimen at 8 weeks after the start of treatment.

8. Ability to attend required study visits and return for adequate follow-up, as required by this protocol.

9. Agreement to practice effective contraception for female subjects of child-bearing potential and non-sterile males. Female subjects of child-bearing potential must agree to use effective contraception for up to 1 year after completion of therapy, and non-sterile male subjects must agree to use a condom for up to 4 months after treatment.

Exclusion Criteria:

1. History of persistent grade 2 or higher (CTCAE Version 4.03) hematologic toxicity resulting from previous therapy.

2. History of other active malignancies or brain metastasis except controlled basal cell carcinoma; prior history of in situ cancer (eg, breast, melanoma, cervical); prior history of prostate cancer that is not under active systemic treatment (except hormonal therapy) and with undetectable prostate-specific antigen (PSA) (< 0.2 ng/mL); and bulky (= 1.5 cm) disease with metastasis in the central hilar area of the chest and involving the pulmonary vasculature. Subjects with a history of another malignancy must have > 5 years without evidence of disease.

3. Serious uncontrolled concomitant disease that would contraindicate the use of the investigational drug used in this study or that would put the subject at high risk for treatment-related complications.

4. Systemic autoimmune disease (eg, lupus erythematosus, rheumatoid arthritis, Addison's disease, autoimmune disease associated with lymphoma).

5. History of organ transplant requiring immunosuppression.

6. History of or active inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis).

7. Requires whole blood transfusion to meet eligibility criteria.

8. Inadequate organ function, evidenced by the following laboratory results:

1. White blood cell (WBC) count < 3,500 cells/mm3.

2. Absolute neutrophil count < 1,500 cells/mm3.

3. Platelet count < 100,000 cells/mm3.

4. Hemoglobin < 9 g/dL.

5. Total bilirubin greater than the upper limit of normal (ULN; unless the subject has documented Gilbert's syndrome).

6. Aspartate aminotransferase (AST [SGOT]) or alanine aminotransferase (ALT [SGPT]) > 2.5 × ULN (> 5 × ULN in subjects with liver metastases).

7. Alkaline phosphatase (ALP) levels > 2.5 × ULN (> 5 × ULN in subjects with liver metastases, or >10 × ULN in subjects with bone metastases).

8. Serum creatinine > 2.0 mg/dL or 177 µmol/L.

9. International normalized ratio (INR) or activated partial thromboplastin time (aPTT) or partial thromboplastin time (PTT) >1.5 × ULN (unless on therapeutic anti-coagulation).

9. Uncontrolled hypertension (systolic > 150 mm Hg and/or diastolic > 100 mm Hg) or clinically significant (ie, active) cardiovascular disease, cerebrovascular accident/stroke, or myocardial infarction within 6 months prior to first study medication; unstable angina; congestive heart failure of New York Heart Association grade 2 or higher; or serious cardiac arrhythmia requiring medication.

10. Dyspnea at rest due to complications of advanced malignancy or other disease requiring continuous oxygen therapy.

11. Positive results of screening test for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV).

12. Current chronic daily treatment (continuous for > 3 months) with systemic corticosteroids (dose equivalent to or greater than 10 mg/day methylprednisolone), excluding inhaled steroids. Short-term steroid use to prevent IV contrast allergic reaction or anaphylaxis in subjects who have known contrast allergies is allowed.

13. Known hypersensitivity to any component of the study medication(s).

14. Subjects taking any medication(s) (herbal or prescribed) known to have an adverse drug reaction with any of the study medications.

15. Concurrent or prior use of a strong cytochrome P450 (CYP)3A4 inhibitor (including ketoconazole, itraconazole, posaconazole, clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole, and grapefruit products) or strong CYP3A4 inducers (including phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, and St John's Wort) within 14 days before study day 1.

16. Concurrent or prior use of a strong CYP2C8 inhibitor (gemfibrozil) or moderate CYP2C8 inducer (rifampin) within 14 days before study day 1.

17. Participation in an investigational drug study or history of receiving any investigational treatment within 14 days prior to screening for this study, except for testosterone-lowering therapy in men with prostate cancer.

18. Assessed by the Investigator to be unable or unwilling to comply with the requirements of the protocol.

19. Concurrent participation in any interventional clinical trial.

20. Pregnant and nursing women.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non-small Cell Lung Cancer

Intervention

Biological:
• avelumab
Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
• Bevacizumab
Recombinant human anti-vascular endothelial growth factor (VEGF) immunoglobulin (Ig) G1 monoclonal antibody

Drug:
• Capecitabine
5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
• Cisplatin
(SP-4-2)-diamminedichloroplatinum(II)
• cyclophosphamide
2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
• 5-Fluorouracil (5-FU)
5-fluoro-2,4 (1H,3H)-pyrimidinedione
• fulvestrant
7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl]estra-1,3,5-(10)- triene-3,17-beta-diol
• leucovorin
Calcium N-[p-[[[(6RS)-2-amino-5- formyl-5,6,7,8-tetrahydro-4-hydroxy-6- pteridinyl]methyl]amino]benzoyl]-L-glutamate (1:1)
• nab paclitaxel
5ß,20-Epoxy-1,2a,4,7ß,10ß,13a-hexahydroxytax-11- en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

Biological:
• nivolumab
Human anti-PD-1 IgG4 kappa monoclonal antibody

Drug:
• Lovaza
Omega-3-acid ethyl esters
• Oxaliplatin
cis-[(1 R,2 R)-1,2-cyclohexanediamine-N,N'] [oxalato(2-)- O,O'] platinum

Radiation:
• Stereotactic Body Radiation Therapy
(SRBT)

Biological:
• ALT-803
recombinant human super agonist interleukin-15 (IL-15) complex [also known as IL15N72D:IL-15RaSu/IgG1 Fc complex]
• ETBX-011
adenovirus serotype-5 [Ad5] [E1-, E2b-]-carcinoembryonic antigen [CEA] vaccine
• ETBX-021
Ad5 [E1-, E2b-]-human epidermal growth factor receptor 2 [HER2] vaccine
• ETBX-051
Ad5 [E1-, E2b-]-Brachyury vaccine
• ETBX-061
Ad5 [E1-, E2b-]-mucin 1 [MUC1] vaccine
• GI-4000
Ras yeast vaccine
• GI-6207
CEA yeast vaccine
• GI-6301
Brachyury yeast vaccine
• haNK
NK-92 [CD16.158V, ER IL-2], Suspension for Intravenous [IV] Infusion

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
ImmunityBio, Inc.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of treatment-emergent adverse events (AEs) and serious AEs (SAEs), graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03.	Phase 1b primary endpoint (safety)	1 year
Primary	Objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1	Phase 2 primary endpoint (ORR by RECIST)	1 year
Primary	ORR by Immune-related response criteria (irRC )	Phase 2 primary endpoint (ORR by irRC)	1 year
Secondary	ORR by RECIST Version 1.1	Phase 1b secondary endpoint (ORR by RECIST)	1 year
Secondary	ORR by irRC	Phase 1b secondary endpoint (ORR by irRC)	1 year
Secondary	Progression-free survival (PFS) by RECIST Version 1.1	Phase 1b and 2 secondary endpoint (PFS by RECIST)	2 years
Secondary	PFS by irRC	Phase 1b and 2 secondary endpoint (PFS by irRC)	2 years
Secondary	Overall survival (OS): time from the date of first treatment to the date of death (any cause)	Phase 1b and 2 secondary endpoint (OS)	2 years
Secondary	Duration of response (DR): time from the date of first response (partial response (PR) or complete response (CR)) to the date of disease progression or death (any cause) whichever occurs first	Phase 1b and 2 secondary endpoint (DR)	2 years
Secondary	Disease control rate (DCR): confirmed complete response, partial response, or stable disease lasting for at least 2 months	Phase 1b and 2 secondary endpoint (DCR)	2 months
Secondary	Quality of life (QoL) by patient-reported outcome using the Functional Assessment of Cancer Therapy-Lung (FACT-L)	Phase 1b and 2 secondary endpoint (QoL)	2 years
Secondary	Incidence of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), graded using the NCI CTCAE Version 4.03	Phase 2 secondary endpoint (AEs)	2 years